Intelectin-1 (ITLN1) Val109Asp (rs2274907) polymorphism: Association with circulating Omentin-1 Levels and Metaflammation in Men with Type 2 Diabetes
This cross-sectional study of 225 men with type 2 diabetes demonstrates that the ITLN1 Val109Asp (rs2274907) polymorphism is significantly associated with progressively lower circulating omentin-1 levels and a more adverse meta-inflammatory metabolic profile, with the A allele linked to increased obesity risk.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Inside the human body, fat tissue is far more than a passive storage depot for energy; it is an active chemical factory that constantly releases signals into the bloodstream. These signals, known as adipokines, act like messengers, telling other organs how to handle sugar and how to manage inflammation. One such messenger is a protein called omentin-1, which is produced primarily in the deep abdominal fat that surrounds our internal organs. In a healthy state, omentin-1 helps the body respond better to insulin, the hormone that regulates blood sugar, and it acts as a brake on chronic, low-grade inflammation. However, when this system falters, the body can drift into a state of "metaflammation," a persistent inflammatory condition driven by metabolic excess that is a hallmark of type 2 diabetes. Understanding why some people produce less of this protective protein than others is a key puzzle in modern medicine, as it could explain why some individuals struggle with weight and blood sugar control while others do not.
A team of researchers in India recently set out to solve a specific piece of this puzzle by looking at the genetic instructions that tell the body how to make omentin-1. They focused on a tiny variation in the DNA code, a single letter change in a gene called ITLN1, which is responsible for producing the protein. This variation, known as Val109Asp, exists in three forms within the population: some people carry two copies of the original version, some carry one copy of the original and one of the variant, and others carry two copies of the variant. The scientists wanted to know if this genetic difference influenced how much omentin-1 circulated in the blood and whether it was linked to the metabolic struggles seen in men with type 2 diabetes. To find out, they recruited 225 men who had been diagnosed with the disease for less than five years and carefully measured their body composition, blood sugar levels, and the chemical markers of inflammation in their blood.
The results revealed a clear and striking pattern. The researchers found that the amount of omentin-1 in the blood dropped steadily depending on which genetic version a man carried. Men with two copies of the original gene had the highest levels of the protein, averaging around 749.6 nanograms per liter. Those with one copy of the variant had lower levels, while men with two copies of the variant had the lowest levels of all, averaging just 483.2 nanograms per liter. This genetic difference was not just a matter of protein levels; it was tied to the overall health of the participants. The men with the lowest omentin-1 levels, who carried two copies of the variant, also showed the most unfavorable metabolic profiles. They tended to have higher body mass indices, greater insulin resistance, and more signs of inflammation in their blood compared to their counterparts with the original gene.
The study went further to determine if this genetic variant was directly linked to the likelihood of being obese. By analyzing the data through different statistical models, the researchers found that carrying the variant gene significantly increased the odds of obesity. Specifically, for every additional copy of the variant gene a man carried, his odds of being obese increased by nearly double. This suggests that the genetic code itself plays a role in shaping how the body stores fat and manages inflammation. Furthermore, the team discovered that certain markers in the blood could accurately predict who had low levels of omentin-1. They found that a specific inflammatory protein called IL-8 was an exceptionally strong indicator; its presence in the blood could distinguish men with low omentin-1 from those with normal levels with remarkable accuracy, far better than many other standard measures.
While the study established a strong link between this genetic variant, low levels of the protective protein, and a difficult metabolic profile, the researchers were careful to note what their work did not prove. Because the study was a snapshot in time, it could not determine whether the genetic difference caused the low protein levels and subsequent health issues, or if other factors were at play. Additionally, the findings were specific to men, as the study did not include female participants, leaving open the question of whether these same genetic rules apply to women with type 2 diabetes. The biological mechanism explaining exactly how a single letter change in DNA leads to lower protein production remains uncertain, as previous experiments had not shown that this specific change alters the structure or function of the protein itself. Nevertheless, the work provides a vital piece of the map, connecting a specific genetic variation to a measurable drop in a protective hormone and a broader state of metabolic inflammation, offering a clearer view of the complex biological landscape of type 2 diabetes.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.